Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Lara Jaradat

Psychiatry Wilmington, DE Medical Doctor

NPI 1508839309 CMS profile 576674

825 N Washington St, Wilmington, DE 19801

Open in the dashboard

General payments

$120

8 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Lara Jaradat of Wilmington, DE is reported in the CMS Open Payments database as having received $120 across 8 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 31st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $28 2
2019 General $91 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lara Jaradat
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Lara Jaradat were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Lara Jaradat Psychiatry median Middle half National median
2019 $91 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $28 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Takeda Pharmaceuticals U.S.A., Inc. $32 3 payments
  2. Supernus Pharmaceuticals, Inc. $28 2 payments
  3. Ironshore Pharmaceuticals Inc. $25 1 payment
  4. Janssen Pharmaceuticals, Inc $18 1 payment
  5. Tris Pharma Inc $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $120 8 payments
Products named General payments · program years 2019–2021
  1. Trintellix $32 3 payments
  2. QELBREE $28 2 payments
  3. Jornay PM 20mg capsules (Bottle of 100) $25 1 payment
  4. SPRAVATO $18 1 payment
  5. Dyanavel XR $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

179

Median for Psychiatry: 574

Drug cost

$6,483

Median for Psychiatry: $27,624

Branded share of claims

6.7%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lisdexamfetamine Dimesylate Generic 16 $4,688
Escitalopram Oxalate Generic 26 $467
Lamotrigine Generic 20 $319
Risperidone Generic 27 $228
Venlafaxine Hcl Er Venlafaxine Hcl Brand 12 $221
Trazodone Hcl Generic 20 $208
Sertraline Hcl Generic 27 $183
Zolpidem Tartrate Generic 14 $130
Lorazepam Generic 17 $38

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$3,352

Medicare's payments for the services billed

Medicare patients

21

Average age 61

Services billed

73

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 62%
High blood pressure 52%
Heart failure 0%
Atrial fibrillation 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

8 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record